

Clinical Trial Protocol

Iranian Registry of Clinical Trials

11 Jun 2026

Evaluation of Pantaprazol on cardiac and hepatic iron overload assessed by T2* MRI in patient with major and intermediate Thalassemia

Protocol summary

Summary

Aim of this study is evaluation of Pantaprazol effect on cardiac & hepatic iron overload assessed by T2* MRI in patient with major and intermediate Thalassemia in Amirkabir hospital of Arak. This study clinical trials. Patients with more than 7 years divide in 2 groups. We measure Ferritin and T2* MRI in cardiac and hepatic in two groups in first study. We prescribe 1 milligram in kilogram of Pantaprazol daily before breakfast (maximum dose 40 milligram) for 6 months in intervention group. We don't prescribe drug in control group. We measure Ferritin and T2* MRI in cardiac and hepatic in two groups after 6 months. Inclusion criteria: Patients with major and intermediate Thalassemia; age more than 7 years. Exclusion criteria: Drug intolerance; unwilling to participate in the study; heart failure; hepatitis; HIV

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT2017042220258N40**
Registration date: **2017-09-03, 1396/06/12**
Registration timing: **registered_while_recruiting**

Last update:

Update count: **0**

Registration date

2017-09-03, 1396/06/12

Registrant information

Name

Fariba Farokhi

Name of organization / entity

Arak University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 86 3222 2003

Email address

f.farokhi@arakmu.ac.ir

Recruitment status

Recruitment complete

Funding source

Vice Chancellor for Research, Arak University of Medical Sciences

Expected recruitment start date

2017-04-08, 1396/01/19

Expected recruitment end date

2018-05-09, 1397/02/19

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Evaluation of Pantaprazol on cardiac and hepatic iron overload assessed by T2* MRI in patient with major and intermediate Thalassemia

Public title

Evaluation of Pantaprazol on cardiac and hepatic iron overload in patient with major and intermediate Thalassemia

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: Patients with major and intermediate Thalassemia; age more than 7 years. Exclusion criteria: Drug intolerance; unwilling to participate in the study; heart failure; hepatitis; HIV

Age

From **7 years** old to **139 years** old

Gender

Both

Phase

2-3

Groups that have been masked

No information

Sample size

Target sample size: 50

Randomization (investigator's opinion)

Randomized

Randomization description**Blinding (investigator's opinion)**

Single blinded

Blinding description**Placebo**

Not used

Assignment

Parallel

Other design features

Randomize with random numbers blindness: researcher than complete data don't aware grouping and analyzer don't aware grouping

Secondary Ids

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics committee of Arak University of Medical Sciences

Street address

Dr Mohammad Rafie, Vice Chancellor Research, Payambar Azam complex, Basij square, Sardasht, Arak

City

Arak

Postal code

38149578558

Approval date

2017-03-06, 1395/12/16

Ethics committee reference number

IR.ARAKMU.REC.1395.434

Health conditions studied**1****Description of health condition studied**

major and intermediate Thalasemia

ICD-10 code

D56.1

ICD-10 code description

Beta thalassaemia

Primary outcomes**1****Description**

Feritin in serum

Timepoint

before and 6 months after 6 treatment

Method of measurement

Blood test

2**Description**

Heart and liver iron load

Timepoint

before and 6 months after 6 treatment

Method of measurement

MRI * 2T

Secondary outcomes

empty

Intervention groups**1****Description**

Intervention group: We prescribe 1 milligram in kilogram of Pantaprazol daily before breakfast (maximum dose 40 milligram) for 6 months in intervention group.

Category

Treatment - Drugs

2**Description**

Intervention group: We don't prescribe drug in control group.

Category

Treatment - Drugs

Recruitment centers**1****Recruitment center****Name of recruitment center**

Amirkabir hospital

Full name of responsible person

Dr Aziz Eghbali

Street address

Amirkabir hospital, Parastar square, Arak

City

Arak

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Vice Chancellor for Research, Arak University of Medical Sciences

Full name of responsible person

Dr Mohammad Rafiee

Street address

Vice chancellor for research, Payambar Azam
Complex, Basij square, Sardasht, Arak

City

Arak

Grant name

-

Grant code / Reference number

-

**Is the source of funding the same sponsor
organization/entity?**

Yes

Title of funding source

Vice Chancellor for Research, Arak University of Medical
Sciences

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

Person responsible for general inquiries

Contact

Name of organization / entity

Arak University of Medical Sciences

Full name of responsible person

Atefeh Khalilpour

Position

medicine student

Other areas of specialty/work

Street address

medicine department, Payambarazam complex, Basij
square, Sardasht, Arak

City

Arak

Postal code

3814957558

Phone

+98 86 3417 3638

Fax

+98 863222003

Email

khalipour@gmail.com

Web page address

-

**Person responsible for scientific
inquiries**

Contact

Name of organization / entity

Arak University of Medical Sciences

Full name of responsible person

Dr Aziz Eghbali

Position

Faculty, pediatric oncology

Other areas of specialty/work

Street address

Amirkabir hospital, Parastar square

City

Arak

Postal code

3814957558

Phone

+98 86 3222 2003

Fax

+98 863222003

Email

eghbali@arakmu.ac.ir

Web page address

-

Person responsible for updating data

Contact

Name of organization / entity

Arak University of Medical Sciences

Full name of responsible person

Atefeh Khalilpour

Position

medicine student

Other areas of specialty/work

Street address

Payambar Azam Complex, Basij Square, Sardasht,
Arak

City

Arak

Postal code

3814957558

Phone

+98 86 3222 2003

Fax

+98 863222003

Email

khalilpour@gmail.com

Web page address

-

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty